Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing

Meet Anj, Breast Cancer Survivor and Signatera Patient

Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient

Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

MRD in a minute: Marcus Noel, MD

MRD in a minute: Marcus Noel, md

MRD in a minute: Saum Ghodoussipour, MD

MRD in a minute: Saum Ghodoussipour, md

MRD in a minute: John Sfakianos, MD

MRD in a minute: John Sfakianos, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, MD

MRD in a minute: Caroline Koffke, bsn, rn

MRD in a minute: Caroline Koffke, BSN, RN

MRD in a minute: Signatera™ Genome

MRD in a minute: Signatera™ Genome CC

MRD in a minute: Changing how cancer is managed

MRD in a minute: Changing how cancer is managed